

## Supporting Information

### Highly specific enrichment of N-linked glycopeptides based on hydrazide functionalized soluble nanoparticles

*Lijuan Zhang, Hucong Jiang, Jun Yao, Yali Wang, Caiyun Fang, Pengyuan Yang and Haojie Lu\**

#### Experiment details

##### Chemicals and reagents

Asialofetuin from fetal calf serum, myoglobin from equine heart, avidin from egg white, invertase from baker's yeast, dithiothreitol (DTT), iodoacetamide (IAA), sodium periodate (NaIO<sub>4</sub>), sodium sulfite (NaSO<sub>3</sub>), sodium acetate (CH<sub>3</sub>COONa), ammonium bicarbonate (NH<sub>4</sub>HCO<sub>3</sub>), methyl acrylate, methanol, urea,  $\alpha$ -cyano-4-hydroxycinnamic acid (CHCA), and L-1-tosylamido-2-phenylethylchloromethyl ketone (TPCK) treated trypsin from bovine pancreas, and PAMAM dendrimer (ethylenediamine core, generation 5.0 solution, provided as 5 wt. % in methanol), *p*-toluenesulfonyl hydrazide (polymer-bound, 100-200 mesh) were purchased from Sigma (St. Louis, MO, USA). BcMag™ Hydrazide-terminated magnetic beads (1  $\mu$ m) was obtained from Bioclone (San Diego, CA, USA). Acetonitrile (ACN, 99.9%), trifluoroacetic acid (TFA) and formic acid (FA) were purchased from Merck (Darmstadt, Germany). Peptide-N-glycosidase (PNGase F) was obtained from New England Biolabs (Ipswich, MA, USA). Sep-Pak C18 columns were from Waters (Milford, MA, USA). Affi-Gel Hz hydrazide Gel was purchased from Bio-Rad (Hercules, CA, USA). Human serum sample was obtained from a healthy donor and stored at -80 °C before analysis. Pure water was prepared with a Milli-Q system (Millipore, Bedford, MA, USA). All other chemicals and reagents were of analytical grade and obtained from Shanghai Chemical Reagent.

##### Synthesis of hydrazide functionalized PAMAM

Methyl acrylate (60  $\mu$ L) in 1.5 mL methanol was added dropwise to PAMAM (2 mL, 5 wt. % in methanol) over a period and then stirred at 0 °C for 24 h. Both solvent and the residue methyl acrylate were removed with a rotatory evaporator. After drying in vacuum at 40 °C, hydrazine hydrate (160  $\mu$ L) in 2 mL methanol was added dropwise to the intermediate, PAMAM with methyl ester terminals, which was re-dissolved in 2 mL methanol and then refluxed and stirred at 120 °C for 3 h. The solvent and residue hydrazine hydrate were removed with a rotary evaporator and dried in vacuum at 60 °C for 24 h.

### **Characterization**

<sup>1</sup>H NMR measurements were carried out on Varian Mercury plus 400NMR spectrometer (400 MHz, 298 K) with dimethyl sulfoxide-d<sub>6</sub> (DMSO-d<sub>6</sub>) as the solvent. Fourier-transform infrared (FT-IR) spectra were collected on a Nicolet Fourier spectrophotometer, using KBr pellets (USA).

### **Preparation of standard protein digests**

Standard glycoprotein (asialofetuin, avidin, invertase) was prepared as 1 mg/mL solution in 25 mM ammonium bicarbonate (pH 8.5), and heated at 95 °C for 5 min. After cooling to room temperature, the solution was treated with trypsin at 37 °C (enzyme/protein ratio of 1:50, w/w) for 18 h. Digestion was stopped by heating the solution at 95 °C for 5 min, and the obtained protein tryptic digests were stored at -20 °C before use.

### **Enrichment of N-linked glycopeptides with hydrazide functionalized PAMAM**

1 mg dried tryptic peptides were re-dissolved in 200 μL coupling buffer (100 mM sodium acetate, 150 mM NaCl, pH 5.5) using a 10 kDa MWCO filter (Vivacon® 500, Sartorius Stedium Biotech, Goettingen, Germany). To oxidize the cis-diol groups of carbohydrates to aldehydes, sodium periodate at 10 mM final concentration was introduced into the peptide solution, and the sample was incubated at room temperature for 1 h with continuous shaking. Then sodium sulfite was added to 20 mM final concentration and incubated for 10 min to deactivate the excess oxidant. After introducing hydrazide functionalized PAMAM (20 μL) into the quenched peptide solution, the coupling reaction was performed at 37 °C overnight with continuous shaking. After the coupling reaction, the excess unreacted reagents, the salts in the coupling buffer, and those non-bound peptides were removed into the filtrate collection through centrifugation at 4 °C for 30 min. The glycopeptide-bound material was washed thoroughly and sequentially with 1.5 M NaCl, 30% MeOH, 0.1% TFA in 10% ACN, and 50 mM ABC and followed by a buffer exchange step to 50 mM ABC. Enzymatic cleavage of the N-linked peptides from the sugar moiety was carried out at 37 °C overnight by PNGase F at a concentration of 1 μL of PNGase F/1 mg of crude proteins. The supernatant, containing the released deglycosylated peptides, was collected into a new collection tube by centrifugation while the PAMAM material and the enzymes remained in the filter. The human serum sample was kindly provided by Fudan University Shanghai cancer center. The research followed the tenets of the Declaration of Helsinki and was approved by the Ethics Committee of the Fudan University Shanghai cancer center.

### **Deglycosylation of N-linked glycopeptides by PNGase F**


Tryptic digestion of the glycoprotein (100 μg) was dissolved in 100 μL 25 mM ammonium bicarbonate (pH 8.5), 0.1 μL PNGase F (500 units per μL) was added to the solution and incubated overnight at 37 °C for N-glycan release. The reaction was stopped by heating to 95 °C for 5 min, and then directly spotted on the MALDI target plate or analysis by nano-LC-MS/MS.

### **Database search and data analysis**


The raw data was initially converted into MGF format with MM File conversion software (Version 3.9). The acquired MS/MS spectra were searched against Swiss-Prot database using MASCOT software (version 2.3). The search criteria were set as follows: variable modifications of methionine oxidation (+16 Da), N-terminal acetylation, and deamidation (N) and fixed

modification of cysteine residues (+57 Da), at most two missed tryptic cleavage sites, 20 ppm error tolerance in MS and 1.00 Da error tolerance in MS/MS. The resulting data files were exported with the filtrations of significance threshold  $p < 0.01$  and ion score  $\geq 25$ . Since N-glycosylation occurs at a consensus N-X-S/T(X≠P) sequon, the remaining peptide sequences were additionally filtered to remove non-motif containing peptides.

**Figure S1.**  $^1\text{H}$  NMR spectra of (A) the original reactant (G5 PAMAM), (B) the intermediate (PAMAM with methyl ester terminals), and (C) the final product (hydrazide functionalized PAMAM).




**Scheme S1** Schematic illustration of hydrazide functionalized PAMAM based glycopeptide enrichment strategy using FASP mode.




For proof-of-principle experiments, the cis-diols of the glycans on glycopeptides were firstly oxidized to obtain the reactive aldehyde groups. After adding the home-made functionalized PAMAM into the coupling buffer, the hydrazide on the surface could react with these aldehyde groups efficiently under mild conditions. Both the oxidation and conjugation steps would be

carried out in a common ultrafiltration device with appropriate molecular weight cutoff (MWCO), and in our study we chose the 10 kDa MWCO filter. Aided by the filter device, the excess unreacted reagents, the salts in the coupling buffer, and the non-bound peptides were removed into the filtrate collection tube easily and quickly. After this, the glycopeptide-bound material was thoroughly washed by a series of washing buffers. These washing steps were also carried out in the same filter device, thus avoiding the possible sample loss during the transfer procedure and making all the captured glycopeptides remain on the filter. Finally, PNGase F was added to release the glycopeptides bound to the material into the solution. And this time the recovered glycopeptides were collected in a new collection tube while the PAMAM material and the enzymes remained on the filter. The schematic illustration of the whole procedure is shown in Scheme S1 (ESI†).

**Figure S2** Plots graphically displaying the tendency between the S/N value of the formerly N-linked glycosylated peptide (VVHAVEVALATFNAESNGSYLQLVEISR) and the concentration of asialofetuin.



**Figure S3** MALDI-TOF MS spectra of tryptic digest mixture of asialofetuin and myoglobin (with a mole ratio of asialofetuin : myoglobin = 1:10) by (A) direct analysis or (B) analysis after enrichment with hydrazide functionalized PAMAM and then deglycosylated by PNGase F. (The asterisk denotes the deglycosylated glycopeptide, the pound sign denotes the doubly charged species, and the circle denotes the unknown peak cluster.)



**Table S1** Results of LTQ analysis of N-glycopeptides isolated from the three-glycoprotein mixture.

Standard glycoprotein	Sequences of identified glycopeptides <sup>a</sup>	Theoretical glycosylation sites	Identified glycosylation sites
Asialofetuin	K.LCPDCPLLAPL <u>N</u> DSR.V R.KLCPDCPLLAPL <u>N</u> DSR.V R.VVHAVEVALATFNAES <u>N</u> GSYLQLVEISR.A R.RPTGEVYDIEIDTLETTCHVLDPTPLAN <u>C</u> SVR.Q	3	3
Chicken avidin	K.WTNDLGS <u>N</u> MTIGAVNSR.G	1	1
Invertase	R.FAT <u>N</u> TTLTK.A K.NPVLAAN <u>S</u> TQFR.D K.AEPIL <u>N</u> ISNAGPWSR.F K.NPVLAAN <u>S</u> TQFRDPK.V K.R <u>N</u> DSGAFSGSMVVDY <u>N</u> NTSGFF <u>N</u> DTIDPR.Q K.ANSYNVDLS <u>N</u> STGTLEFELVYAV <u>N</u> TTQTISK.S K.FSLNTEYQANPETELINLKAEPIL <u>N</u> ISNAGPWSR.F	13	8

<sup>a</sup> N denotes the N-linked glycosylation site.

**Table S2.** List of identified glycoproteins from 5 µL human plasma captured by hybrid hydrazide functionalized PAMAM. N denotes the N-linked glycosylation site.

Protein accession number	Protein name/Protein group	Peptide sequence
AFAM_HUMAN	Afamin OS=Homo sapiens GN=AFM PE=1 SV=1	DIENF <u>N</u> STQK
AFAM_HUMAN	Afamin OS=Homo sapiens GN=AFM PE=1 SV=1	YAEDKF <u>N</u> ETTEK
A1AG1_HUMAN	Alpha-1-acid glycoprotein 1 OS=Homo sapiens GN=ORM1 PE=1 SV=1	EN <u>G</u> TISR
A1AG1_HUMAN	Alpha-1-acid glycoprotein 1 OS=Homo sapiens GN=ORM1 PE=1 SV=1	QDQCIY <u>N</u> TTYLVNQR
A1AG1_HUMAN	Alpha-1-acid glycoprotein 1 OS=Homo sapiens GN=ORM1 PE=1 SV=1	QDQCIY <u>N</u> TTYLVNQRE <u>N</u> GTI SR
A1AG2_HUMAN	Alpha-1-acid glycoprotein 2 OS=Homo sapiens GN=ORM2 PE=1 SV=2	NEEY <u>N</u> K
A1AG2_HUMAN	Alpha-1-acid glycoprotein 2 OS=Homo sapiens GN=ORM2 PE=1 SV=2	NEEY <u>N</u> KSVQEIQATFFYFTP <u>N</u> KTEDTIFLR
A1AG2_HUMAN	Alpha-1-acid glycoprotein 2 OS=Homo sapiens GN=ORM2 PE=1 SV=2	QNQCFY <u>N</u> SSYLVNQR

A1AG2_HU MAN	Alpha-1-acid glycoprotein 2 OS=Homo sapiens GN=ORM2 PE=1 SV=2	QNQCFYNSSYLNVQRENGT VSR
AACT_HU MAN	Alpha-1-antichymotrypsin OS=Homo sapiens GN=SERPINA3 PE=1 SV=2	APDKNVIFSPLSISTALAFLS LGAHNTTLEILK
AACT_HU MAN	Alpha-1-antichymotrypsin OS=Homo sapiens GN=SERPINA3 PE=1 SV=2	FNLTETSEAEIHQSFQHLLR
AACT_HU MAN	Alpha-1-antichymotrypsin OS=Homo sapiens GN=SERPINA3 PE=1 SV=2	GLKFNL TETSEAEIHQSFQH LLR
AACT_HU MAN	Alpha-1-antichymotrypsin OS=Homo sapiens GN=SERPINA3 PE=1 SV=2	KLINDYVKNGTR
AACT_HU MAN	Alpha-1-antichymotrypsin OS=Homo sapiens GN=SERPINA3 PE=1 SV=2	LINDYVKNGTR
AACT_HU MAN	Alpha-1-antichymotrypsin OS=Homo sapiens GN=SERPINA3 PE=1 SV=2	YTGNASALFILPDQDK
AACT_HU MAN	Alpha-1-antichymotrypsin OS=Homo sapiens GN=SERPINA3 PE=1 SV=2	YTGNASALFILPDQDKMEE VEAMLLPETLK
AACT_HU MAN	Alpha-1-antichymotrypsin OS=Homo sapiens GN=SERPINA3 PE=1 SV=2	YTGNASALFILPDQDKMEE VEAMLLPETLKR
A1AT_HU MAN	Alpha-1-antitrypsin OS=Homo sapiens GN=SERPINA1 PE=1 SV=3	ADTHDEILEGLNFNLTETIPEA QIHEGFQELLR
A1AT_HU MAN	Alpha-1-antitrypsin OS=Homo sapiens GN=SERPINA1 PE=1 SV=3	QLAHQSNSTNIFFSPVSIATA FAMLSLGTK
A1AT_HU MAN	Alpha-1-antitrypsin OS=Homo sapiens GN=SERPINA1 PE=1 SV=3	YLGNATAIFFLPDEGK
A1AT_HU MAN	Alpha-1-antitrypsin OS=Homo sapiens GN=SERPINA1 PE=1 SV=3	YLGNATAIFFLPDEGKLQHL ENELTHDIITK
A1BG_HU MAN	Alpha-1B-glycoprotein OS=Homo sapiens GN=A1BG PE=1 SV=3	EGDHEFLEVPEAQEDVEATF PVHQPGNYSCSYR
FETUA_HU MAN	Alpha-2-HS-glycoprotein OS=Homo sapiens GN=AHSG PE=1 SV=1	AALAAFNAQNNGSNFQLEEI SR
A2MG_HU MAN	Alpha-2-macroglobulin OS=Homo sapiens GN=A2M PE=1 SV=2	GCVLLSYLNETVTVSASLES VR
A2MG_HU MAN	Alpha-2-macroglobulin OS=Homo sapiens GN=A2M PE=1 SV=2	GNEANYYSNATTDEHGLVQ FSINTTNVMGTSLTVR
A2MG_HU MAN	Alpha-2-macroglobulin OS=Homo sapiens GN=A2M PE=1 SV=2	VSNQTLSLFFTVLQDVPVR
ANGT_HU MAN	Angiotensinogen OS=Homo sapiens GN=AGT PE=1 SV=1	VYIHPFHLVIHNESTCEQLA K
ANT3_HU MAN	Antithrombin-III OS=Homo sapiens GN=SERPINC1 PE=1 SV=1	AAINKWVSNKTEGR
ANT3_HU MAN	Antithrombin-III OS=Homo sapiens GN=SERPINC1 PE=1 SV=1	LFGDKSLTFNETYQDISELV YGAK
ANT3_HU MAN	Antithrombin-III OS=Homo sapiens GN=SERPINC1 PE=1 SV=1	LGACNDTLQQLMEVFK

ANT3_HU MAN	Antithrombin-III OS=Homo sapiens GN=SERPINC1 PE=1 SV=1	LGACNDTLQQLMEVFKFDT ISEK
ANT3_HU MAN	Antithrombin-III OS=Homo sapiens GN=SERPINC1 PE=1 SV=1	LVSANRLFGDKSLTFNETYQ DISELVYGAK
ANT3_HU MAN	Antithrombin-III OS=Homo sapiens GN=SERPINC1 PE=1 SV=1	SLTFNETYQDISELVYGAK
APOB_HU MAN	Apolipoprotein B-100 OS=Homo sapiens GN=APOB PE=1 SV=1	FEVDSPVYNATWSASLK
APOB_HU MAN	Apolipoprotein B-100 OS=Homo sapiens GN=APOB PE=1 SV=1	FNSSYLQGTNQITGR
APOB_HU MAN	Apolipoprotein B-100 OS=Homo sapiens GN=APOB PE=1 SV=1	FVEGSHNSTVSLTTK
APOB_HU MAN	Apolipoprotein B-100 OS=Homo sapiens GN=APOB PE=1 SV=1	LATALSLSNKFVEGSHNSTV SLTTK
APOB_HU MAN	Apolipoprotein B-100 OS=Homo sapiens GN=APOB PE=1 SV=1	QVLFLDVTYGNCSHTFTVK
APOB_HU MAN	Apolipoprotein B-100 OS=Homo sapiens GN=APOB PE=1 SV=1	VNQNLVYESGSLNFSK
APOB_HU MAN	Apolipoprotein B-100 OS=Homo sapiens GN=APOB PE=1 SV=1	VNQNLVYESGSLNFSKLEIQ SQVDSQHVGHSVLTAK
APOB_HU MAN	Apolipoprotein B-100 OS=Homo sapiens GN=APOB PE=1 SV=1	YDFNSSMLYSTAK
APOC4_HU MAN	Apolipoprotein C-IV OS=Homo sapiens GN=APOC4 PE=1 SV=1	ELLETVVNR
APOC4_HU MAN	Apolipoprotein C-IV OS=Homo sapiens GN=APOC4 PE=1 SV=1	MKELLETVVNR
APOD_HU MAN	Apolipoprotein D OS=Homo sapiens GN=APOD PE=1 SV=1	ADGTVNQIEGEATPVNLTEP AK
APOD_HU MAN	Apolipoprotein D OS=Homo sapiens GN=APOD PE=1 SV=1	ADGTVNQIEGEATPVNLTEP AKLEVK
APOD_HU MAN	Apolipoprotein D OS=Homo sapiens GN=APOD PE=1 SV=1	CIQANYSLMENGK
ATRN_HU MAN	Attractin OS=Homo sapiens GN=ATRN PE=1 SV=2	DLDMFINASK
ATRN_HU MAN	Attractin OS=Homo sapiens GN=ATRN PE=1 SV=2	IDSTGNVTNELR
ATRN_HU MAN	Attractin OS=Homo sapiens GN=ATRN PE=1 SV=2	VFHIHNESWVLLTPK
APOH_HU MAN	Beta-2-glycoprotein 1 OS=Homo sapiens GN=APOH PE=1 SV=3	LGNWSAMPSCK
APOH_HU MAN	Beta-2-glycoprotein 1 OS=Homo sapiens GN=APOH PE=1 SV=3	VYKPSAGNNSLYR
BTD_HUM AN	Biotinidase OS=Homo sapiens GN=BTD PE=1 SV=2	DVQIIVFPEDGIHGFNFTR



BTD_HUMAN	Biotinidase OS=Homo sapiens GN=BTD PE=1 SV=2	NPVGLIGAENATGETDPSHSK
CBPB2_HUMAN	Carboxypeptidase B2 OS=Homo sapiens GN=CPB2 PE=1 SV=1	KQVHFFV <u>N</u> ASDV <u>D</u> NVK
CBPB2_HUMAN	Carboxypeptidase B2 OS=Homo sapiens GN=CPB2 PE=1 SV=1	QVHFFV <u>N</u> ASDV <u>D</u> NVK
CPN2_HUMAN	Carboxypeptidase N subunit 2 OS=Homo sapiens GN=CPN2 PE=1 SV=2	AFGSNP <u>N</u> LTK
CERU_HUMAN	Ceruloplasmin OS=Homo sapiens GN=CP PE=1 SV=1	AGLQAFFQVQEC <u>N</u> K
CERU_HUMAN	Ceruloplasmin OS=Homo sapiens GN=CP PE=1 SV=1	AGLQAFFQVQEC <u>N</u> KSSSK
CERU_HUMAN	Ceruloplasmin OS=Homo sapiens GN=CP PE=1 SV=1	AGLQAFFQVQEC <u>N</u> KSSSKDNIR
CERU_HUMAN	Ceruloplasmin OS=Homo sapiens GN=CP PE=1 SV=1	EHEGAIYPD <u>N</u> TTDFQR
CERU_HUMAN	Ceruloplasmin OS=Homo sapiens GN=CP PE=1 SV=1	ELHHLQEQ <u>N</u> VSNAFLDK
CERU_HUMAN	Ceruloplasmin OS=Homo sapiens GN=CP PE=1 SV=1	ELHHLQEQ <u>N</u> VSNAFLDKGEFYIGSK
CERU_HUMAN	Ceruloplasmin OS=Homo sapiens GN=CP PE=1 SV=1	E <u>N</u> LTPGSDSAVFFEQGTTR
CERU_HUMAN	Ceruloplasmin OS=Homo sapiens GN=CP PE=1 SV=1	NLASRPYTFHSHGITYYKEHEGAIYPD <u>N</u> TTDFQR
CLUS_HUMAN	Clusterin OS=Homo sapiens GN=CLU PE=1 SV=1	EDAL <u>N</u> ETR
CLUS_HUMAN	Clusterin OS=Homo sapiens GN=CLU PE=1 SV=1	KKEDAL <u>N</u> ETR
CLUS_HUMAN	Clusterin OS=Homo sapiens GN=CLU PE=1 SV=1	LAN <u>L</u> TQGEDQYYLR
CLUS_HUMAN	Clusterin OS=Homo sapiens GN=CLU PE=1 SV=1	ML <u>N</u> TSSLLEQLNEQFNWVSR
C1QA_HUMAN	Complement C1q subcomponent subunit A OS=Homo sapiens GN=C1QA PE=1 SV=2	NPPMGGNVVIFDTVITNQEEPYQ <u>N</u> HSGR
C1QA_HUMAN	Complement C1q subcomponent subunit A OS=Homo sapiens GN=C1QA PE=1 SV=2	RNPPMGGNVVIFDTVITNQEEPYQ <u>N</u> HSGR
C1R_HUMAN	Complement C1r subcomponent OS=Homo sapiens GN=C1R PE=1 SV=2	EHEAQSN <u>A</u> SLDVFLGHTNVEELMK
CO2_HUMAN	Complement C2 OS=Homo sapiens GN=C2 PE=1 SV=2	QSVPAHFVAL <u>N</u> GSK
CO4A_HUMAN	Complement C4-A OS=Homo sapiens GN=C4A PE=1 SV=1	FSDGLES <u>N</u> SSTQFEVK
CO4A_HUMAN	Complement C4-A OS=Homo sapiens GN=C4A PE=1 SV=1	FSDGLES <u>N</u> SSTQFEVKK

CO4A_HUMAN	Complement C4-A OS=Homo sapiens GN=C4A PE=1 SV=1	GL <u>N</u> VTLSS <u>T</u> GR
CO4A_HUMAN	Complement C4-A OS=Homo sapiens GN=C4A PE=1 SV=1	GL <u>N</u> VTLSS <u>T</u> GRNGFK
CO6_HUMAN	Complement component C6 OS=Homo sapiens GN=C6 PE=1 SV=3	LSS <u>N</u> STKK
CO6_HUMAN	Complement component C6 OS=Homo sapiens GN=C6 PE=1 SV=3	VL <u>N</u> FTTK
CO8A_HUMAN	Complement component C8 alpha chain OS=Homo sapiens GN=C8A PE=1 SV=2	GGSSGWSGGLA <u>Q</u> NR
CO9_HUMAN	Complement component C9 OS=Homo sapiens GN=C9 PE=1 SV=2	AV <u>N</u> ITSENLI <u>D</u> DVVSLIR
CFAB_HUMAN	Complement factor B OS=Homo sapiens GN=CFB PE=1 SV=2	IVLDPSGSMNIYL <u>V</u> LDGSDSI GAS <u>N</u> FTGAK
CFAB_HUMAN	Complement factor B OS=Homo sapiens GN=CFB PE=1 SV=2	IVLDPSGSMNIYL <u>V</u> LDGSDSI GAS <u>N</u> FTGAKK
CFAB_HUMAN	Complement factor B OS=Homo sapiens GN=CFB PE=1 SV=2	KIVLDPSGSMNIYL <u>V</u> LDGSD SIGAS <u>N</u> FTGAK
CFAB_HUMAN	Complement factor B OS=Homo sapiens GN=CFB PE=1 SV=2	KIVLDPSGSMNIYL <u>V</u> LDGSD SIGAS <u>N</u> FTGAKK
CFAH_HUMAN	Complement factor H OS=Homo sapiens GN=CFH PE=1 SV=4	IPCSQPPQIEHGT <u>I</u> NSR
CFAH_HUMAN	Complement factor H OS=Homo sapiens GN=CFH PE=1 SV=4	MDGAS <u>N</u> VTCINSR
CBG_HUMAN	Corticosteroid-binding globulin OS=Homo sapiens GN=SERPINA6 PE=1 SV=1	AQLLQGLGF <u>N</u> LTER
CBG_HUMAN	Corticosteroid-binding globulin OS=Homo sapiens GN=SERPINA6 PE=1 SV=1	AVLQLNEEGVDTAGSTGVT L <u>N</u> LTSKPIILR
FINC_HUMAN	Fibronectin OS=Homo sapiens GN=FN1 PE=1 SV=3	DQCIVDDITYNV <u>N</u> DTFHK
FINC_HUMAN	Fibronectin OS=Homo sapiens GN=FN1 PE=1 SV=3	LDAPTNLQFV <u>N</u> ETDSTVLVR
LG3BP_HUMAN	Galectin-3-binding protein OS=Homo sapiens GN=LGALS3BP PE=1 SV=1	ALGF <u>E</u> NATQALGR
LG3BP_HUMAN	Galectin-3-binding protein OS=Homo sapiens GN=LGALS3BP PE=1 SV=1	GL <u>N</u> LTEDTYKPR
LG3BP_HUMAN	Galectin-3-binding protein OS=Homo sapiens GN=LGALS3BP PE=1 SV=1	YKGL <u>N</u> LTEDTYKPR
HPT_HUMAN	Haptoglobin OS=Homo sapiens GN=HP PE=1 SV=1	MVSHH <u>N</u> LTTGATLINEQWL LTTAK
HPT_HUMAN	Haptoglobin OS=Homo sapiens GN=HP PE=1 SV=1	NLFLNHSE <u>N</u> ATAK
HPT_HUMAN	Haptoglobin OS=Homo sapiens GN=HP PE=1 SV=1	VVLHP <u>N</u> YSQVDIGLIK

HEMO_HUMAN	Hemopexin OS=Homo sapiens GN=HPX PE=1 SV=2	ALPQPQN <u>V</u> TSLLGCTH
HEMO_HUMAN	Hemopexin OS=Homo sapiens GN=HPX PE=1 SV=2	GHGHRNGTGHGN <u>S</u> THHGPEYMR
HEMO_HUMAN	Hemopexin OS=Homo sapiens GN=HPX PE=1 SV=2	<u>N</u> GTGHGN <u>S</u> THHGPEYMR
HGFA_HUMAN	Hepatocyte growth factor activator OS=Homo sapiens GN=HGFA PE=1 SV=1	DSVSVVLGQHFF <u>N</u> R
HRG_HUMAN	Histidine-rich glycoprotein OS=Homo sapiens GN=HRG PE=1 SV=1	IADAHLD <u>R</u> V <u>E</u> NTTVYYLVL DVQESDCSVLSR
HRG_HUMAN	Histidine-rich glycoprotein OS=Homo sapiens GN=HRG PE=1 SV=1	VIDF <u>N</u> CTTSSVSSALANTK
IGHA1_HUMAN	Ig alpha-1 chain C region OS=Homo sapiens GN=IGHA1 PE=1 SV=2	LAGKPTHV <u>N</u> VSVVMAEVD GTCY
IGHA1_HUMAN	Ig alpha-1 chain C region OS=Homo sapiens GN=IGHA1 PE=1 SV=2	LSLHRPALEDLLL <u>G</u> SEAN <u>L</u> T CTLTGLR
IGHG1_HUMAN	Ig gamma-1 chain C region OS=Homo sapiens GN=IGHG1 PE=1 SV=1	EEQY <u>N</u> STYR
IGHG1_HUMAN	Ig gamma-1 chain C region OS=Homo sapiens GN=IGHG1 PE=1 SV=1	EEQY <u>N</u> STYRVVSVLTVLHQ DWLNGKEYK
IGHG2_HUMAN	Ig gamma-2 chain C region OS=Homo sapiens GN=IGHG2 PE=1 SV=2	EEQF <u>N</u> STFR
IGHG3_HUMAN	Ig gamma-3 chain C region OS=Homo sapiens GN=IGHG3 PE=1 SV=2	EEQY <u>N</u> STFR
IGHM_HUMAN	Ig mu chain C region OS=Homo sapiens GN=IGHM PE=1 SV=3	GLTFQ <u>Q</u> NASSMCPDQDTA IR
IGHM_HUMAN	Ig mu chain C region OS=Homo sapiens GN=IGHM PE=1 SV=3	YK <u>N</u> NSDISSTR
IGJ_HUMAN	Immunoglobulin J chain OS=Homo sapiens GN=IGJ PE=1 SV=4	E <u>N</u> ISDPTSPLR
IGJ_HUMAN	Immunoglobulin J chain OS=Homo sapiens GN=IGJ PE=1 SV=4	IIVPLNNRE <u>N</u> ISDPTSPLR
ITIH1_HUMAN	Inter-alpha-trypsin inhibitor heavy chain H1 OS=Homo sapiens GN=ITIH1 PE=1 SV=3	ANLSSQALQMSLDYGFVTP LTSMSIR
ITIH1_HUMAN	Inter-alpha-trypsin inhibitor heavy chain H1 OS=Homo sapiens GN=ITIH1 PE=1 SV=3	DKICDLLVANNHFAHFFAPQ <u>N</u> LTNM <u>N</u> K
ITIH2_HUMAN	Inter-alpha-trypsin inhibitor heavy chain H2 OS=Homo sapiens GN=ITIH2 PE=1 SV=2	GAFIS <u>N</u> FSMTVDGK
ITIH4_HUMAN	Inter-alpha-trypsin inhibitor heavy chain H4 OS=Homo sapiens GN=ITIH4 PE=1 SV=4	AFIT <u>N</u> FSMIIDGMTYP <u>G</u> IIK
ITIH4_HUMAN	Inter-alpha-trypsin inhibitor heavy chain H4 OS=Homo sapiens GN=ITIH4 PE=1 SV=4	AFIT <u>N</u> FSMIIDGMTYP <u>G</u> IIKE K
ITIH4_HUMAN	Inter-alpha-trypsin inhibitor heavy chain H4 OS=Homo sapiens GN=ITIH4 PE=1 SV=4	GPDVLTATVSGKLPTQ <u>N</u> ITF QTESSVAEQEAEFQSPK

ITIH4_HUMAN	Inter-alpha-trypsin inhibitor heavy chain H4 OS=Homo sapiens GN=ITIH4 PE=1 SV=4	KAFITNFSMIIDGMTYPGIK
ITIH4_HUMAN	Inter-alpha-trypsin inhibitor heavy chain H4 OS=Homo sapiens GN=ITIH4 PE=1 SV=4	LPTQNITFQTESSVAEQEAEFQSPK
ITIH4_HUMAN	Inter-alpha-trypsin inhibitor heavy chain H4 OS=Homo sapiens GN=ITIH4 PE=1 SV=4	LQDRGPDVLTATVSGKLPTQNTFQTESSVAEQEAEFQSPK
ITIH4_HUMAN	Inter-alpha-trypsin inhibitor heavy chain H4 OS=Homo sapiens GN=ITIH4 PE=1 SV=4	NQALNLSLAYSFVTPLTSMV VTKPDDQEQSQVAEKPMEG ESR
KAIN_HUMAN	Kallistatin OS=Homo sapiens GN=SERPINA4 PE=1 SV=3	DFYVDENTTVR
KAIN_HUMAN	Kallistatin OS=Homo sapiens GN=SERPINA4 PE=1 SV=3	FLNDTMAVYEAK
KNG1_HUMAN	Kininogen-1 OS=Homo sapiens GN=KNG1 PE=1 SV=2	ITYSIVQTNCSK
KNG1_HUMAN	Kininogen-1 OS=Homo sapiens GN=KNG1 PE=1 SV=2	KYNSQNSNNQFVLYR
KNG1_HUMAN	Kininogen-1 OS=Homo sapiens GN=KNG1 PE=1 SV=2	LNAENNTATFYFK
KNG1_HUMAN	Kininogen-1 OS=Homo sapiens GN=KNG1 PE=1 SV=2	YNSQNSNNQFVLYR
A2GL_HUMAN	Leucine-rich alpha-2-glycoprotein OS=Homo sapiens GN=LRG1 PE=1 SV=2	KLPPGLLANFTLLR
A2GL_HUMAN	Leucine-rich alpha-2-glycoprotein OS=Homo sapiens GN=LRG1 PE=1 SV=2	LPPGLLANFTLLR
A2GL_HUMAN	Leucine-rich alpha-2-glycoprotein OS=Homo sapiens GN=LRG1 PE=1 SV=2	MFSQNDTR
LUM_HUMAN	Lumican OS=Homo sapiens GN=LUM PE=1 SV=2	AFENVTDLQWLILDHNLLEN NSK
LUM_HUMAN	Lumican OS=Homo sapiens GN=LUM PE=1 SV=2	KLHINHNNLTESVGPLPK
LUM_HUMAN	Lumican OS=Homo sapiens GN=LUM PE=1 SV=2	LGSFEGLVNLTFIHLQHNR
LUM_HUMAN	Lumican OS=Homo sapiens GN=LUM PE=1 SV=2	LHINHNNLTESVGPLPK
LUM_HUMAN	Lumican OS=Homo sapiens GN=LUM PE=1 SV=2	LSHNELADSGIPGNSFNVS LVELDLSYNK
PHLD_HUMAN	Phosphatidylinositol-glycan-specific phospholipase D OS=Homo sapiens GN=GPLD1 PE=1 SV=3	LGTSLSGGHVLNMGTLK
PHLD_HUMAN	Phosphatidylinositol-glycan-specific phospholipase D OS=Homo sapiens GN=GPLD1 PE=1 SV=3	LNVEAANWTVR

PLTP_HUMAN	Phospholipid transfer protein OS=Homo sapiens GN=PLTP PE=1 SV=1	IYSNHSALSLALIPLQAPLK
KLKB1_HUMAN	Plasma kallikrein OS=Homo sapiens GN=KLKB1 PE=1 SV=1	GVNFNVSK
KLKB1_HUMAN	Plasma kallikrein OS=Homo sapiens GN=KLKB1 PE=1 SV=1	IYPGVDFGGEELNVTFVK
KLKB1_HUMAN	Plasma kallikrein OS=Homo sapiens GN=KLKB1 PE=1 SV=1	IYSGILNLSDITK
KLKB1_HUMAN	Plasma kallikrein OS=Homo sapiens GN=KLKB1 PE=1 SV=1	IYSGILNLSDITKDTPFSSQIK
IC1_HUMAN	Plasma protease C1 inhibitor OS=Homo sapiens GN=SERPING1 PE=1 SV=2	DTFVN <sup>u</sup> NASR
IC1_HUMAN	Plasma protease C1 inhibitor OS=Homo sapiens GN=SERPING1 PE=1 SV=2	GVTSVVSQIFHSPDLAIRDTFVN <sup>u</sup> NASR
IC1_HUMAN	Plasma protease C1 inhibitor OS=Homo sapiens GN=SERPING1 PE=1 SV=2	VGQLQLSHNLSLVILVPQNLK
IC1_HUMAN	Plasma protease C1 inhibitor OS=Homo sapiens GN=SERPING1 PE=1 SV=2	VLSNNSDANLELINTWVAK
ZPI_HUMAN	Protein Z-dependent protease inhibitor OS=Homo sapiens GN=SERPINA10 PE=1 SV=1	ETFFNLSK
ZPI_HUMAN	Protein Z-dependent protease inhibitor OS=Homo sapiens GN=SERPINA10 PE=1 SV=1	LPYQGNATMLVVLMEK
THRB_HUMAN	Prothrombin OS=Homo sapiens GN=F2 PE=1 SV=2	GHVN <sup>u</sup> ITR
TRFE_HUMAN	Serotransferrin OS=Homo sapiens GN=TF PE=1 SV=2	CGLVPVLAENYN <sup>u</sup> K
PON1_HUMAN	Serum paraoxonase/arylesterase 1 OS=Homo sapiens GN=PON1 PE=1 SV=2	HANWTLTPLK
PON1_HUMAN	Serum paraoxonase/arylesterase 1 OS=Homo sapiens GN=PON1 PE=1 SV=2	VTQVYAENGTVLQGSTVASVYK
PON1_HUMAN	Serum paraoxonase/arylesterase 1 OS=Homo sapiens GN=PON1 PE=1 SV=2	VTQVYAENGTVLQGSTVASVYK GK
TSP1_HUMAN	Thrombospondin-1 OS=Homo sapiens GN=THBS1 PE=1 SV=2	VVN <sup>u</sup> STTGPGHELR
TITIN_HUMAN-R	TITIN_HUMAN-R	KNLSPGIR
ZA2G_HUMAN	Zinc-alpha-2-glycoprotein OS=Homo sapiens GN=AZGP1 PE=1 SV=1	AREDIFMETLKDIVEYYN <sup>u</sup> DSNGSHVLQGR
ZA2G_HUMAN	Zinc-alpha-2-glycoprotein OS=Homo sapiens GN=AZGP1 PE=1 SV=1	DIVEYYN <sup>u</sup> DSNGSHVLQGR